|
ITC: The FMCG major's standalone net profit rose 21.38% to Rs 5,086.86 crore on 5.12% increase in net sales to Rs 16,115.9 crore in Q4 FY23 over Q4 FY22. The company sustained its strong growth momentum across all operating segments during the period under review. InterGlobe Aviation (IndiGo): IndiGo reported a consolidated net profit of Rs 919.20 crore in Q4 FY23 as against a net loss of Rs 1,681.79 crore in Q4 FY22. Revenue from operations surged 76.55% to Rs 14,160.60 crore in the quarter ended 31 March 2023 from Rs 8,020.74 crore recorded in Q4 FY22. Wipro: Wipro announced a five-year business partnership with ServiceNow to invest in and bring new offerings to market that will empower clients to drive business transformation, overcome business challenges, and deliver greater value. The agreement expands on the two companies' existing partnership and is expected to help accelerate Wipro's goal of building a $1 billion business with ServiceNow by the end of 2026. United Spirits: The company reported a consolidated net profit of Rs 102.80 crore in Q4 FY23 as against a net profit of Rs 178.6 crore in Q4 FY22. Revenue from operations advanced to Rs 5809.6 crore in the quarter ended 31 March 2023 from Rs 7791.1 crore recorded in Q4 FY22. Tata Elxsi: The company reported 25.9% rise in consolidated net profit to Rs 201.5 crore on 22.9% rise in revenue to Rs 837.9 crore in the quarter ended 31 March 2023 over the quarter ended 31 March 2022. Bata India: The company reported a consolidated net profit of Rs 65.6 crore in Q4 FY23 as against a net profit of Rs 62.9 crore in Q4 FY22. Total income advanced to Rs 788.5 crore in the quarter ended 31 March 2023 from Rs 683.9 crore recorded in Q4 FY22. Pfizer: The company has decided to initiate a voluntary recall of( i) Magnex 1gm, 2gm; (ii) Magnex Forte 1.5gm, 3gm; (iii) Zosyn 4.5gm; and (iv) Magnamycin 250mg, 1gm, 2gm injections (Products) manufactured by Astral SteriTech Private and marketed/distributed by Pfizer. The voluntary recall is likely to have an impact on the revenue and profitability of the company. The products recorded a sale of Rs 139 crore for the year ended 31 March 2023. Granules India: The drug maker has received US drug regulator's approval for its Abbreviated New Drug Application (ANDA) for Venlafaxine Hydrochloride extended-release capsules. Nexus Select Trust: The real estate investment trust will debut on the bourses today, 19 May 2023. The issue price has been fixed at Rs 100 per unit. Powered by Capital Market - Live News
|